Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
NCT04220008 · M.D. Anderson Cancer Center · PHASE2 · withdrawn · last registry update 2024-01-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No Participants Enrolled” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RRM1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-12-19Phase 3 first posted: Immatics US, Inc., IMA203 + nivolumab plus relatlimab (NCT06743126)
- 2024-12-03Phase 3 first posted: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, High intensity therapies + Low intensity therapies (NCT06713837)
- 2024-10-16Results posted on the registry: National Cancer Institute (NCI), Cisplatin + Triapine (NCT02595879)
- 2024-10-02Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Cisplatin (NCT06623422)
- 2024-10-01Phase 3 first posted: InnoPharmax Inc., D07001-Softgel Capsules + Placebo (NCT06622057)
- 2024-10-01Phase 3 first posted: Genmab, Rina-S + Paclitaxel (NCT06619236)
- 2024-09-26Phase 3 first posted: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, BMS-986393 + Cyclophosphamide (NCT06615479)
- 2024-09-23Phase 3 first posted: Arcus Biosciences, Inc., Quemliclustat + Placebo (NCT06608927)
- 2024-08-26Results posted on the registry: Hoffmann-La Roche, Alectnib + Cisplatin (NCT03456076)
- 2024-08-09Phase 3 first posted: Ferring Pharmaceuticals, Nadofaragene Firadenovec + Gemcitabine (NCT06545955)
- 2024-07-29Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT06524544)
- 2024-06-21Phase 3 first posted: AstraZeneca, Gemcitabine + Cisplatin (NCT06467357)
- 2024-06-14Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab Tirumotecan + Pemetrexed (NCT06459180)
- 2024-06-03Phase 3 first posted: Novartis Pharmaceuticals, Crizanlizumab + Placebo (NCT06439082)
- 2024-03-25Phase 3 first posted: Cabaletta Bio, CABA-201 + CABA-201 (NCT06328777)
- 2024-03-20Phase 3 first posted: Janssen Research & Development, LLC, TAR-210 + Gemcitabine (NCT06319820)
- 2024-03-15Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06312137)
- 2024-02-28Phase 3 first posted: Jazz Pharmaceuticals, Zanidatamab + Cisplatin (NCT06282575)
- 2024-01-18Phase 3 first posted: Janssen Research & Development, LLC, TAR-200 + Mitomycin C (NCT06211764)
- 2024-01-08Results posted on the registry: Novartis Pharmaceuticals, Crizanlizumab (SEG101) + Placebo (NCT03814746)
- 2024-01-05Results posted on the registry: National Cancer Institute (NCI), Cisplatin + Triapine (NCT02466971)
- 2023-12-04Phase 3 first posted: Cabaletta Bio, CABA-201 following preconditioning with fludarabine and cyclophosphamide (NCT06154252)
- 2023-11-18Phase 3 first posted: Tokyo Medical and Dental University, Systemic therapy for 12 weeks after primary registration + Same systemic therapy after secondary registration (NCT06135714)
- 2023-11-03Phase 3 first posted: Alliance for Clinical Trials in Oncology, Nab paclitaxel + Gemcitabine (NCT06115499)
- 2023-10-31Phase 3 first posted: AstraZeneca, Rilvegostomig + Placebo (NCT06109779)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision